



Please scan this QR Code to view the RHP)



# AAKAAR MEDICAL TECHNOLOGIES LIMITED

Corporate Identity Number: U74900MH2013PLC244717

Our Company was originally incorporated as 'Aakaar Medical Technologies Private Limited', a private limited company under Companies Act, 1956, pursuant to a certificate of incorporation dated June 20, 2013, issued by the Registrar of Companies, Mumbai, Maharashtra. Subsequently, our Company was converted into a public limited company pursuant to a resolution passed by our shareholders at an Extra-ordinary General meeting held on July 19, 2024 and a fresh certificate of incorporation dated November 18, 2024 was issued by the RoC, Central Processing Centre consequent upon conversion, recording the change in name of our Company from 'Aakaar Medical Technologies Private Limited' to 'Aakaar Medical Technologies Limited'

**Registered Office:** 801, Heritage Plaza, Telli Galli Cross Road, Andheri (East), Mumbai-400069, Maharashtra, India.  
**Contact Person:** Anoopkumar Vishwanathan Pillai, Company Secretary and Compliance Officer; **Tel:** +91 84528 44024  
**E-mail:** companysecretary@akaarmedical.in **Website:** www.akaarmedical.in

**THIS ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018 ("SEBI ICDR REGULATIONS") (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED (NSE EMERGE)**

**BID/OFFER OPENS ON FRIDAY, JUNE 20, 2025\*\*** **BID/OFFER CLOSES ON TUESDAY, JUNE 24, 2025#**

**\*\*Our Company may, in consultation with the BRLM, consider closing the Bid/Issue Period for QIBs 1 (one) Working Day prior to the Bid/Issue Closing Date in accordance with the SEBI/ICDR Regulations.**

**#The UPI mandate end time and date shall be at 5:00 p.m. on Bid/Issue Closing Day**

## NOTICE TO THE INVESTORS: CORRIGENDUM TO THE RED HERRING PROSPECTUS DATED JUNE 14, 2025 READ WITH ANY CORRIGENDA, THERETO ("THE CORRIGENDUM")

This corrigendum ("Corrigendum") is with reference to the Red Herring Prospectus dated June 14, 2025 ("RHP") read with any corrigenda, thereto filed in relation to the proposed initial public offering of up to 37,50,400 having of face value of ₹10 each ("Equity Shares") for cash at a price of ₹[•] per Equity Share (including a securities premium of ₹[•] per Equity Share) aggregating up to ₹[•] Lakhs ("PUBLIC ISSUE")

This Corrigendum forms a part of the RHP, supplements the information in the RHP and the changes below are to be read in conjunction with the RHP. Accordingly, relevant references in the RHP stand updated pursuant to the disclosure in this Corrigendum. In this regard, please note the following:

Chapter	Page No.	Details of change/ Modification	
The Issue	59		
		b) Balance of QIB Portion for all QIBs including Mutual Funds	Up to 6,75,200 Equity Shares aggregating up to ₹ [•] Lakhs
		B. Non-Institutional Portion	Not less than 5,34,400 Equity Shares aggregating up to ₹ [•] Lakhs
		Below the table in the RHP will be read as below: *Subject to finalization of the Basis of Allotment. Number of shares may need to be adjusted for lot size upon determination of Issue price. The Face Value of Equity Shares is ₹ 10 each	
Issue Structure	282		
		Particulars (2)	Non-Institutional Bidders / Investors
		Number of Equity Shares available for Allotment/ allocation*	Not less than 5,34,400 Equity Shares available for allocation or Issue less allocation to QIBs and Retail Individual Bidders

The RHP shall be read in conjunction with this Corrigendum and accordingly the RHP stands amended pursuant to this Corrigendum. The information in this Corrigendum supplements the RHP to the extent set out above and will also be disclosed in the Prospectus as and when filed with the RoC, SEBI and the Stock Exchange. This Corrigendum does not reflect all the changes that have occurred between the date of filing of the RHP and the date hereof, and, accordingly, does not include all the changes and/or updates that will be included in the Prospectus.

All capitalized terms used in this Corrigendum shall, unless the context otherwise requires, have the meaning ascribed to such terms in the RHP

BOOK RUNNING LEAD MANAGER	REGISTRAR TO THE ISSUE
 <b>Indorient Financial Services Limited</b> B/805, Rustomjee Central Park Andheri Kurla Road, Chakala Mumbai – 400 093 Maharashtra, India <b>Telephone:</b> +91 9819934811 <b>Email:</b> compliance-ifsl@indorient.in <b>Website:</b> www.indorient.in <b>Investor Grievance Id:</b> wecare@indorient.in <b>Contact Person:</b> Vinit Shah <b>SEBI Registration No.:</b> INM000012661	 <b>Bigshare Services Private Limited</b> Office No. S6-2, 6th Floor Pinnacle Business Park, next to Ahura Center Mahakali Caves Road, Andheri East Mumbai-400093 <b>Telephone:</b> +91 22 62638200 <b>E-mail:</b> ipo@bigshareonline.com <b>Investor grievance email:</b> investor@bigshareonline.com <b>Website:</b> www.bigshareonline.com <b>Contact Person:</b> Vinayak Morbale <b>SEBI Registration No:</b> INR000001385

All capitalized terms used herein and not specifically defined shall have the same meaning ascribed to it in the RHP.

**Date:** June 18, 2025

**Place:** Mumbai

**For Aakaar Medical Technologies Limited**  
**On behalf of the Board of Directors**  
**Sd/-**  
**Anoopkumar Vishwanathan Pillai**  
**Company Secretary and Compliance Officer**

Aakaar Medical Technologies Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market considerations and other considerations to undertake an initial public offer of its Equity Shares and has filed the RHP dated June 14, 2025 with SME platform of National Stock Exchange of India Limited ("NSE EMERGE") and ROC. The RHP is available on the website of the NSE at [www.nseindia.com](http://www.nseindia.com), as well as on the website of Book Running Lead Manager at [www.indorient.in](http://www.indorient.in) and the Company at [www.akaarmedical.in](http://www.akaarmedical.in). Investors should note that investment in Equity Shares involves a high degree of risk and for details relating to the same, see "Risk Factors" on page 28 of the RHP. Potential investors should not rely on the RHP filed with the ROC for making any investment decisions. This announcement is not an Issue of securities for sale in United States or in any restricted jurisdiction. This announcement may not be published or distributed in the United States or in any restricted jurisdiction.

The Equity Shares have not been and will not be registered under the U.S. Securities Act or any other applicable law of the United States and, unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold outside the United States in off shore transactions in reliance on Regulation S under the U.S. Securities Act and the applicable laws of each jurisdiction where such offers and sales are made. The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Bids may not be made, by persons in any such jurisdiction except in compliance with the applicable laws of such jurisdiction.